EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus

Thaila Fernanda Dos Reis iD, Camila Diehl, Camila Figueiredo Pinzan, Patrícia Alves de Castro, Gustavo H Goldman iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.00888-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Thaila Fernanda Dos Reis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Antifungal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aspergillus fumigatus is the primary etiological agent of aspergillosis. Here, we show that the host defense peptide mimetic brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates of A. fumigatus . BRI + IBX can inhibit the growth of A. fumigatus voriconazole- and caspofungin-resistant clinical isolates. BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against viruses, bacteria, and fungi. In vitro , combination of BRI + IBX plays a fungicidal role, increases the fungal cell permeability, decreases the fungal survival in the presence of A549 epithelial cells, and appears as a promising antifungal therapeutic alternative against A. fumigatus . IMPORTANCE Invasive fungal infections have a high mortality rate causing more deaths annually than tuberculosis or malaria. Aspergillus fumigatus causes a series of distinct invasive fungal infections have a high mortality rate causing more deaths annually than tuberculosis or malaria. A. fumigatus causes a spectrum of distinct clinical entities named aspergillosis, which the most severe form is the invasive pulmonary aspergillosis. There are few therapeutic options for treating aspergillosis and searching for new antifungal agents against this disease is very important. Here, we present brilacidin (BRI) as a synergizer o fibrexafungerp (IBX) against A. fumigatus . BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against bacteria and viruses. We propose the combination of BRI and IBX as a new antifungal combinatorial treatment against aspergillosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillus fumigatusAntifungal AgentsHumansDrug SynergismMicrobial Sensitivity TestsAspergillosisA549 CellsAntimicrobial PeptidesDrug Resistance, Fungal

Stichwörter der Autor:innen

Aspergillus fumigatusbrilacidindrug resistanceibrexafungerp

Substanzen

Antifungal AgentsAntimicrobial Peptides

Autor:innen und Institutionen

  • Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
  • National Institute of Science and Technology in Human Pathogenic Fungi, São Paulo, Brazil.

ORCID-Profile: Thaila Fernanda Dos Reis, Gustavo H Goldman

Förderung

  • NIAID NIH HHS
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Dos Reis, T. F., Diehl, C., Pinzan, C. F., de Castro, P. A., & Goldman, G. H. (2024). Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00888-24

Vancouver

Dos Reis TF, Diehl C, Pinzan CF, de Castro PA, Goldman GH. Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00888-24

BibTeX
@article{DosReis2024,
  author = {Dos Reis, Thaila Fernanda and Diehl, Camila and Pinzan, Camila Figueiredo and de Castro, Patrícia Alves and Goldman, Gustavo H},
  title = {Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.00888-24}
}
Kostenlos starten →